MedTrace Logo

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

NCT02683824 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-09-21

No results posted yet for this study

Summary

This pilot clinical trial studies the use of integrin alpha-v-beta \[18F\]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta-6 (avb6), are a family of membrane receptors that are overexpressed on the cell surface of pancreatic cancers. \[18F\]-R01-MG-F2 targets avb6, which may improve early detection of and better stratify treatment options for patients with pancreatic cancer.

Conditions

  • Healthy Subject
  • Pancreatic Carcinoma

Interventions

DIAGNOSTIC_TEST

Computed Tomography

Undergo CT scan

OTHER

Laboratory Biomarker Analysis

Correlative studies

DIAGNOSTIC_TEST

PET/MRI scan

Undergo PET/MRI scan

DRUG

[18F]FP-R01-MG-F2

radioactive tracer

Sponsors & Collaborators

Principal Investigators

  • Andrei Iagaru · Stanford Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-12
Primary Completion
2021-09-27
Completion
2022-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02683824 on ClinicalTrials.gov